Salokangas R K, Saarijärvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, Tuominen J, Ahola V, Syvälahti E
Department of Psychiatry, University of Turku, Finland.
Acta Psychiatr Scand. 1996 Sep;94(3):175-80. doi: 10.1111/j.1600-0447.1996.tb09844.x.
The effects of citalopram--the most selective serotonin reuptake inhibitor on the market--on psychopathological symptoms were studied in chronic schizophrenic patients on a stable regimen of neuroleptic medication. Outpatients suffering from schizophrenic disorder (DSM-III-R) with Positive and Negative Symptom Scale (PANSS) scores higher than 50 were included in a double-blind placebo-controlled add-on study. The daily dose of citalopram was 20 mg in the first week and 40 mg for the remaining period. A total of 90 patients (45 patients receiving citalopram and 45 receiving placebo) completed the 12-week trial. There were no changes in neuroleptic plasma levels during the trial. There was a significant decrease in total PANNS scores during the trial, although no statistically significant differences between the citalopram group and the placebo group were revealed. The number of responders in terms of severity of illness (CGI) was higher and the increase in subjective well-being (VAS) was greater in patients on citalopram than in those receiving placebo. There were no significant differences in the occurrence of side-effects. It is concluded that, in chronic schizophrenic out-patients, citalopram has no clear effect on the psychopathological symptoms; it may improve the general clinical condition, and it appears to increase the subjective well-being of these patients. Citalopram appears to be safe when used to treat schizophrenic patients who are receiving concomitant neuroleptic treatment.
在接受稳定剂量抗精神病药物治疗的慢性精神分裂症患者中，研究了市面上选择性最强的5-羟色胺再摄取抑制剂西酞普兰对精神病理症状的影响。将患有精神分裂症（DSM-III-R）、阳性和阴性症状量表（PANSS）得分高于50的门诊患者纳入一项双盲安慰剂对照附加研究。西酞普兰的日剂量在第一周为20毫克，其余时间为40毫克。共有90名患者（45名接受西酞普兰治疗，45名接受安慰剂治疗）完成了为期12周的试验。试验期间抗精神病药物的血浆水平没有变化。试验期间PANNS总分显著下降，尽管西酞普兰组和安慰剂组之间没有显示出统计学上的显著差异。就疾病严重程度（CGI）而言，服用西酞普兰的患者中有效者数量更多，主观幸福感（VAS）的增加也比服用安慰剂的患者更大。副作用的发生率没有显著差异。得出的结论是，在慢性精神分裂症门诊患者中，西酞普兰对精神病理症状没有明显影响；它可能会改善总体临床状况，而且似乎会提高这些患者的主观幸福感。在用于治疗同时接受抗精神病药物治疗的精神分裂症患者时，西酞普兰似乎是安全的。
